BASF Quote - 1BAS | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
Italy
BIT
BASF AG (1BAS) Share Price

BASF AG (1BAS)

41.60

-1.20

(-2.80%)

Closed January 05 10:30AM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

41.60

Bid

41.40

Ask

44.00

Volume

2,444

41.50 Day's Range 42.22

40.105 52 Week Range 54.84

Market Cap

Previous Close

42.80

Open

42.01

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

1,393

Shares Outstanding

893,436,042

Dividend Yield

-

PE Ratio

0.00

Earnings Per Share (EPS)

-

Revenue

68.9B

Net Profit

225M

Sector

Chems, Allied Pds-whsl, Nec

Industry

Chemicals Diversified

Website

www.basf.com

Headquarters

Ludwigshafen Am Rhein, Deu

Founded

1984

BASF AG is listed in the Chems, Allied Pds-whsl sector of the Italian Stock Exchange with ticker 1BAS. The last closing price for BASF was 42.80 €. Over the last year, BASF shares have traded in a share price range of 40.105 € to 54.84 €.

BASF currently has 893,436,042 shares outstanding. The market capitalization of BASF is 38.24 € billion.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.58	-1.3750592698	42.18	43.1	41.5	1927	42.81201609	DE
4	-2.38	-5.41155070487	43.98	45.62	40.69	1359	43.56213283	DE
12	-5.66	-11.9763013119	47.26	47.69	40.69	1393	43.81851266	DE
26	-3.105	-6.94553181971	44.705	48.64	40.105	1636	44.46197564	DE
52	-7.16	-14.6841673503	48.76	54.84	40.105	1807	46.533588	DE
156	-21.32	-33.8842975207	62.92	68.92	38	3113	47.69562641	DE
260	-26.1	-38.552437223	67.7	73.39	37.5	2560	50.25808088	DE

1BAS - Frequently Asked Questions (FAQ)

What is the current BASF share price?

The current share price of BASF is 41.60 €

How many BASF shares are in issue?

BASF has 893,436,042 shares in issue

What is the market cap of BASF?

The market capitalisation of BASF is EUR 38.24B

What is the 1 year trading range for BASF share price?

BASF has traded in the range of 40.105 € to 54.84 € during the past year

What is the reporting currency for BASF?

BASF reports financial results in EUR

What is the latest annual turnover for BASF?

The latest annual turnover of BASF is EUR 68.9B

What is the latest annual profit for BASF?

The latest annual profit of BASF is EUR 225M

What is the registered address of BASF?

The registered address for BASF is CARL-BOSCH-STRA��E 38, LUDWIGSHAFEN AM RHEIN, 67056

What is the BASF website address?

The website address for BASF is www.basf.com

Which industry sector does BASF operate in?

BASF operates in the CHEMICALS DIVERSIFIED sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WAMB26Ambromobiliare SpA	0.098 € (96.00%)	53.83k
1NBNorthern Data AG	52.50 € (30.76%)	34
EVAAskoll Eva SPA	0.17 € (25.46%)	403k
WSOGESWarr Soges Group	0.115 € (21.05%)	15k
WTFINTrevi Finanziaria Industriale Spa	0.89 € (18.67%)	3.33k
WCOSMOFarmacosmo spa	0.0096 € (-67.89%)	6.67k
COSMOFarmacosmo spa	0.668 € (-22.86%)	338.93k
WTWL26TraWell Co SpA	0.22 € (-21.43%)	600
GTGT Talent Group SpA	2.76 € (-14.29%)	21.38k
WSGC28SG Company SpA	0.025 € (-12.89%)	12.26k
TITTelecom Italia SpA	0.243 € (-2.68%)	128.24M
ISPIntesa Sanpaolo Spa	3.849 € (-0.03%)	47.15M
SPMSaipem Spa	2.717 € (2.07%)	44.36M
ENELEnel Spa	7.023 € (-0.03%)	14.4M
BPEBper Banca SPA	5.90 € (-0.94%)	11.78M

Mr. Bill

Mr. Bill 10 minutes ago

https://www.goodrx.com/well-being/sleep/how-to-sleep-with-sciatica

nowwhat2

nowwhat2 12 minutes ago

Could still just be climbing in sympathy w overall crypto mkt

Scathingly poor outlooks

https://www.youtube.com/watch?v=EOsjnOUAw14

https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

DonVance

DonVance 13 minutes ago

This will hit 1k this year I believe now.

georgejjl

georgejjl 14 minutes ago

How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t

Mr. Bill

Mr. Bill 15 minutes ago

Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch

Graniteguy

Graniteguy 16 minutes ago

Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of

BDEZ

BDEZ 18 minutes ago

The Russes hit the jackpot?

BDEZ

BDEZ 19 minutes ago

40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529

BDEZ

BDEZ 19 minutes ago

Not good, thanks for sharing.

sand

sand 26 minutes ago

Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.

mining101

mining101 27 minutes ago

Moving hard soon

mining101

mining101 28 minutes ago

benz280c

benz280c 35 minutes ago

Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.

rx7171

rx7171 42 minutes ago

In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.

TheHound

TheHound 43 minutes ago

Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!

Investor2014

Investor2014 46 minutes ago

When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw

nowwhat2

nowwhat2 51 minutes ago

Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

Because how the overall mkt resolves itself is gonna'r have con

rx7171

rx7171 52 minutes ago

Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca

sunspotter

sunspotter 57 minutes ago

Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.

Investor2014

Investor2014 59 minutes ago

The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.

nowwhat2

nowwhat2 60 minutes ago

Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

Because how the overall mkt resolves itself is gonna'r have con

sunspotter

sunspotter 1 hour ago

I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.

nowwhat2

nowwhat2 1 hour ago

Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

Because how the overall mkt resolves itself is gonna'r have con

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions